






2013

2014



Significantly diversified our current product offering and revenue sources with the result of revenue dramatically increased by 134% in year 2014 compared with year 2013.



Highlights

Revenue: 355.3m, Y/Y (

Gross Margin, 68%

Net Loss: (59.6m)

Key Financial Summary

USD: million	2014	2013	Flux
Revenue	355.3	151.7	134%
Cost	(112.0)	(28.8)	289%
Gross Profit	243.3	122.9	98%
<i>Gross Margin</i>	<i>68%</i>	<i>81%</i>	
Operating Expenses	(259.0)	(74.1)	250%
Recurring operating profit	(15.7)	48.8	-132%
Other Operating Expense	(35.7)	(21.9)	63%
Net Gain	12.0	7.3	64%
Finance Costs	(13.0)	(1.1)	1128%
Share of losses of JV	(1.2)		
(Loss)/Profit before taxation	(53.5)	33.2	
Net (Loss)/Profit	(59.6)	24.0	



1 Orthopedics Business


2 Vascular Business

3 Electrophysiology and CRM Business

4 Surgical Devices

Stabilizing the MPO Business in 2014

(USD million)



Under Wright Medical Ownership

Overview

The Business owns the brands PATH®,

EVOLUTION®, etc.

US sales: sales force of ~ 150 people

International sales: combination of ~ 100 direct sales force and distributors in non-US markets.

Highlights

100 Day Plan Executed without significant issues.

Secured Global Distribution Network

China outperformed and Latin America & EMEA performed

KOL Recruitment to MPO

Note: 2014 revenue is annualized to include stub period of Jan 1-9, 2014 before acquisition.

**Organic
Business
Performance
Goals**



**Complete transition and
infrastructure investments**



2014 US & Int'l market stabilization


EMEA & ROW growing

2014 = Global Revenue Drivers:





Global Infrastructure Investments:






Strategic Foundation



no muscles tendons
none of the typical postoperative hip restrictions

tissue-sparing
approach requires

SuperPath® Hip Replacement
▶ Fast Forward™



-
- ❖ **AAOS Annual Meeting - New Orleans**
 - ❖ **The 15th Annual Meeting of Asia-Pacific Arthroplasty Society ---**



践行正道
MicroPort Orthopedics

2014年第三届 微创骨科关节外科新技术学习班 MicroPort Orthopedics Training Program on TKA&THA

2014年10月12 - 14日

上海微创骨科医疗科技有限公司

践行正道
MicroPort Orthopedics


2014年第三届微创人工关节置换新技术
学习班将于10月12-14日在
上海浦东新区张江高科技园区张东路1601号
微创集团总部大楼

人工关节外科的现状与未来》、《膝关节微创机器人新技术》、《膝关节设计新理念》
大师问道》、《人工关节置换热点讨论》、《专家分享疑难病例》、
《专家做习生》、吴海山、周一新，鼎力担任本次大会的主席。同时，美国专家
how 将莅临现场，分享 Superpath® — 全球最新的膝关节后外侧微创入路手术技术。
参与和分享，携手缔造精彩！

上海微创骨科医疗科技有限公司
2014年6月



China DES Market Share 2014



Firehawk Update

- ☒ CFDA approved in Jan, 2014
- ☒ CE Mark obtained in Jan, 2015
- ☒ Premium MNC Price Achieved

Third generation DES

The World's First and Only **target-eluting stent**

The largest pre-market clinical study in China ensures high credibility of safety and efficacy

The lowest dosage of drug amongst all DES's maintains excellent efficacy

Solid evidence-based medical data paves the way for world-wide introduction

- ☒ **Conor Assets purchase agreement on Jan 2014, acquired:**

The World's **First** and **Only** Target Eluting Stent (TES)







With the lowest drug dosage


Targeted unidirectional eluting technology with fully biodegradable polymers

Unique position identification/recognition & state-of-the-art 3D printing technologies


The largest pre-market clinical study following the most stringent protocol in China

Solid evidence-based medical data





TAA/AAA 2014 Market Share




Products Profile


Hercules T



Hercules B




Castor




Branched Aortic Stent-Graft and Delivery System
 Successful Clinical Trial closing report announced on Jan 2015

Solid Growth of Endovascular in Revenue




Complete share restructure to employee motivation scheme



Dramatic Growth of Electrophysiology in Revenue

USD: million



Products on the China Market



Products with CE Certifications

FireMagic



Radiofrequency Ablation Catheter

EasyFinder



Fixed or adjustable Curved Mapping Catheter

EasyLoop



Circumferential Pulmonary Vein Mapping Catheter

FireMagic 3D



Saline Infusion Radiofrequency Ablation Catheter

Columbus



3D EP Navigation System

Anchor



External Reference Patch

- **The Only Chinese company to have full EP product line**
- **Launched in CE & China market**
- **Achieved overseas sales of 3-D mapping systems in Dominican Republic, Turkey and Greece in 2014**



Our Vision

Helping patients live better and longer through our quality pacing products and services innovated and made in China, for China and the world

Our Goal

To strive for the #1 position in local pacing segment in China

Imported Sorin Products on the China Market



**Smallest
Physiologic
Dual Sensor**

Made 1st sell in
Sep, 2014

Innovated in China, for China



IPGs
Leads
Programmer
Biz Models
Others

Building a manufacturing line in Shanghai


Animal study on going

Aiming to initiate human trial in 2015

Leveraging MP & Sorin capabilities



Cardiac Intervention




Successfully completed the first human implantation on Sep 2014.

In the stage of clinical

Advantages

- *Be implanted using a revolutionary interventional chest*
- *With less pain*
- *Faster recovery*

Surgical Robot



Set up the project on May, 2014

The core team has been set up, including 10 R&D engineers

In the stage of animal experiment


The 1st successfully implantation of the aortic heart valve and Surgical Robot R&D mark that research and development ability has reached a new level.

❑ Education to Advance Expertise and Care

- — → MP Foundation in University of Shanghai for Science and Technology
- — → Medical Device Library and Information Center in USST

❑ Care Goes Beyond the Office

— —



Revenue	355,284	151,655
Cost of sales	(111,999)	(28,777)
Gross profit	243,285	122,878
Other revenue & net income	12,025	7,320
Research and development costs	(54,564)	(29,195)
Distribution costs	(133,629)	(25,630)
Administrative expenses	(70,773)	(19,259)
Other operating costs	(35,710)	(21,897)
Operating Profit	(39,366)	34,217
Finance costs	(12,956)	(1,055)
Share of losses of a joint venture	(1,192)	
(Loss)/profit before taxation	(53,514)	33,162
Income tax	(6,057)	

USD'000	31 Dec 2014	31 Dec 2013
Fixed assets	286,666	154,897
Intangible assets	60,506	34,280
Prepayments for fix assets	1,678	1,092
Goodwill	56,529	25,577
Deferred tax assets	4,124	3,197
Interest in a joint venture	3,866	-
Deposits with banks	11,440	-
Other non-current receivables	6,813	-
Total non-current assets	431,622	219,043
Inventories	109,901	20,314
Trade and other receivables	121,930	63,264
Deposits with banks	60,679	56,322
Cash and cash equivalents	215,602	159,903
Total current assets	508,112	299,803
Total assets	939,734	518,846
Trade and other payables	(108,649)	(45,506)
Interest-bearing borrowings	(215,897)	(29,629)
Income tax payable	(1,016)	(2,848)
Deferred income	(10)	(14)
Derivative financial liabilities	(592)	-
Obligation under finance leases	(1,868)	-
Total current liabilities	(328,032)	(77,997)
Interest-bearing borrowings	(132,817)	(21,964)
Convertible bond	(91,573)	-
Obligation under finance leases	(1,894)	-
Deferred income	(28,989)	(16,982)
Other payables	(1,793)	-
Other non-current liabilities	(7,335)	(7,053)
Deferred tax liabilities	(3,558)	(4,417)
Total liabilities	(595,991)	(128,413)
Share capital	(14)	(14)
Capital reserve	(342,239)	(390,419)
Non controlling interest	(1,490)	-
Total equity	(343,743)	(390,433)

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Thank You



The Patient Always Comes First

